CannabisNewsBreaks

FridayJan 26, 2018 2:31 pm

CannabisNewsBreaks – DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) Aims to Multiply Production Capabilities in 2018

Premium cannabis lifestyle brand DOJA Cannabis Company (CSE: DOJA) (OTC: DJACF) is a licensed marijuana producer under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The company recently expanded its production capacity through the acquisition of a new warehouse. A recent article discussing the company reads: “As a licensed cannabis producer under the ACMPR through its wholly-owned subsidiary Northern Lights Marijuana Company, DOJA currently operates a 7,100-square-foot production facility that is licensed by Health Canada. The company recently acquired second facility is a 22,580-square-foot warehouse where its FUTURE LAB will be housed. The FUTURE LAB will be a state-of-the-art…

Continue Reading

ThursdayJan 25, 2018 3:55 pm

CannabisNewsBreaks – Choom Holdings, Inc. (CSE: CHOO) (OTCQB: CHOOF) Debuts Concept of Retail Dispensary; Engages Design Team

Canadian cannabis cultivation company, Choom™ (CSE: CHOO) (OTCQB: CHOOF), recently confirmed that is has embarked on an innovative retail dispensary strategy by releasing its concept of a new retail store design. The company remains focused on engaging recreational and lifestyle brands in the legal cannabis market, and intends to be a major player reaching Canadian cannabis consumers. Choom’s retail dispensary strategy aims to exploit the burgeoning market sector in areas of Canada that permit the private distribution of recreational cannabis through developing a chain of branded retail cannabis dispensaries. In an effort to remain a step ahead of the competition,…

Continue Reading

WednesdayJan 24, 2018 3:13 pm

CannabisNewsBreaks – True Leaf Medicine International Ltd. (CSE: MJ) (FSE: TLA) (OTCQB: TRLFF) Secures New Equity Financing

True Leaf Medicine International (CSE: MJ) (FSE: TLA) (OTCQB: TRLFF) this morning said it has raised C$14 million in equity financing that will enable the life cannabis company to move forward with its medicinal cannabis facility. True Leaf raised C$10M in a Regulation A+ public equity offering priced at C$0.70 per share, making it the first Canadian-listed company to successfully conduct such an offering. Additionally, the company said it is currently working toward the close of a $4,051,654.60 non-brokered private placement via the sale of 5,788,078 common shares at a price of C$0.70 per share, available to Canadian investors only.…

Continue Reading

WednesdayJan 24, 2018 2:46 pm

CannabisNewsBreaks – Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) Secures $2M in Private Placement

On January 22, Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) said that it closed a non-brokered private placement financing of 5,000,000 units at a price of $0.40 each. Each unit consists of one common share and one-half of one transferable share purchase warrant. Each whole warrant entitles the holder to further purchase one common share for a period of up to twenty-four months at a price of $0.60. The company also issued 259,485 finder's units with the same entails. The company received total gross proceeds of $2,000,000 from the offering which it intends to use toward fast-tracking…

Continue Reading

WednesdayJan 24, 2018 11:26 am

CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Enhances Life by Uniting Nature and Science

An ongoing concern in North America, as reported by the Centers for Disease Control and Prevention, is that Americans are only taking advantage of preventive medical services about half as often as they should. Endeavoring to become a pioneer in preventative medicine, health science company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was founded on the belief that, in healthcare, prevention is the best policy, and that nature and science can unite to offer a range of innovative, untapped solutions to address unmet clinical needs. As quoted in a recent article: “PreveCeutical is taking a new look at…

Continue Reading

WednesdayJan 24, 2018 11:19 am

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Platform Expands Portfolio

Food bioscience company Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) strategic focus for 2018 is on out-licensing its proprietary technology, DehydraTECH™. The company intends to out-license to third-party partners using a high margin royalty model. An article discussing the company’s drug delivery platform reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million Insights (http://cnw.fm/fGid9), the global API market is anticipated to reach $239.8 billion by 2025, with…

Continue Reading

FridayJan 19, 2018 12:24 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Eyes Bright Future Following 2017 Success

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) demonstrated several transformative developments in 2017. The company’s Intellectual Property (“IP”) was strengthened, it was awarded broad patents, and it secured finances during the year. Now, Lexaria is concentrating on making 2018 an even more fruitful year. An article discussing the company’s recent progress reads: “The company’s stock has performed well over the last year and, given all the progress, may outperform in 2018. Lexaria up-listed to the larger, more recognized OTCQX market, and the company filed an S4 prospectus to re-domicile the company from the U.S. to Canada in an effort to exploit…

Continue Reading

ThursdayJan 18, 2018 11:09 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Subsidiary Receives Import License from Australia

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF), through wholly-owned subsidiary ABcann Australia Pty Ltd., this morning announced that it has received an import license from the Federal Office of Drug Control in Australia. Following receipt of necessary approvals, including approval from the TSX Venture Exchange, ABcann intends to supply medicinal cannabis to the Australian market via the Australian Department of Health’s Therapeutic Goods Administration (“TGA”) Special Access Scheme. “This import license is a key milestone towards generating revenue through ABcann’s network of physicians, pharmacists and patients, and advancing the use of medical cannabis,” Barry Fishman, chief executive officer of ABcann,…

Continue Reading

TuesdayJan 09, 2018 11:47 am

CannabisNewsBreaks – DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) Completes $12.5 Million Private Placement

Premium cannabis lifestyle brand DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) this morning announced the closing of its previously outlined non-brokered private placement of subscription receipts, whereby Aphria Inc. (TSX: APH) (OTC: APHQF) and Koicha Partners LP acquired from DOJA an aggregate of roughly nine million subscription receipts at a price per unit of $1.39, generating gross proceeds of $12.5 million. Per the update, this financing is intended to support the strategic positioning of Hiku Brands Company Ltd., the anticipated combined company resulting from the merger of DOJA and Tokyo Smoke. “We're thrilled to have strategic partners in Aphria…

Continue Reading

TuesdayJan 09, 2018 10:08 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Responds to Cole Memo Repeal

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning issued a follow-up statement to the memorandum issued by Attorney General Jeff Sessions on January 4, 2018, concerning marijuana enforcement and the repeal of the Cole Memo. In the update, Veritas noted that the AG’s decision largely relates to the recreational cannabis marketplace, in which individual states have allowed sales over the last 24 months. Conversely, the company notes, it does not affect the medical cannabis marketplace. As such, Veritas intends to build on its commitment to advancing the science of medical cannabis…

Continue Reading